Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Schweizer Gastroenterologie 2/2023

Open Access 07.06.2023 | Morbus Crohn | Originalien

Morbus Crohn Update

verfasst von: Dr. med. Andrea S. Kreienbuehl, PD Dr. med. Luc Biedermann

Erschienen in: Schweizer Gastroenterologie | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der chronische Krankheitsverlauf beim Morbus Crohn macht nicht selten eine lebenslange immunmodulatorische oder immunsuppressive Therapie nötig. Das therapeutische Spektrum wurde seit der Zulassung von Infliximab massgeblich erweitert. Nebst den TNF-Inhibitoren konnten sich Ustekinumab und Vedolizumab etablieren und stellen je nach Schwere respektive Ausdehnung der Erkrankung sowie unter Einbezug von extraintestinalen Manifestationen oder Komorbiditäten gleichwertige Erstlinientherapien dar. Als neuste Therapieoption stehen Risankizumab (Anti-IL-23) und voraussichtlich auch bald Upadacitinib kurz vor der Schweizer Marktzulassung. Kombinationstherapien – verschiedene Biologika oder Biologika + JAK-Inhibitoren – rücken weiter in den Fokus zukünftiger Therapiealgorithmen, und erste Resultate der Phase-3-Studie (Guselkumab/Golimumab) dürfen im nächsten Jahr erwartet werden. Weiterhin schwer therapierbar sind komplexe Verläufe bei Analfisteln, wobei sich in einer gut selektionierten Patientengruppe ein erfreuliches Ansprechen auf die mesenchymale Stammzelltherapie zeigt. Nebst den medikamentösen Therapieoptionen, sollte die Chirurgie (insbesondere Ileozökalresektion) in ihrem Stellenwert nicht vernachlässigt werden und kann je nach Ausgangslage – auch in einem frühen Erkrankungsstadium – ein valabler Therapieansatz sein.
Literatur
1.
Zurück zum Zitat Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46–54 e42 (quiz e30) PubMedCrossRef Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46–54 e42 (quiz e30) PubMedCrossRef
2.
Zurück zum Zitat Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE et al (2019) Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in asia-pacific. Am J Gastroenterol 114(1):107–115 PubMedCrossRef Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE et al (2019) Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in asia-pacific. Am J Gastroenterol 114(1):107–115 PubMedCrossRef
3.
Zurück zum Zitat Crohn BB, Ginzburg L, Oppenheimer GD (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67(3):263–268 PubMed Crohn BB, Ginzburg L, Oppenheimer GD (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67(3):263–268 PubMed
4.
Zurück zum Zitat Zhou M, He J, Shen Y, Zhang C, Wang J, Chen Y (2017) New frontiers in genetics, gut microbiota, and immunity: a Rosetta stone for the pathogenesis of inflammatory bowel disease. Biomed Res Int 2017:8201672 PubMedPubMedCentralCrossRef Zhou M, He J, Shen Y, Zhang C, Wang J, Chen Y (2017) New frontiers in genetics, gut microbiota, and immunity: a Rosetta stone for the pathogenesis of inflammatory bowel disease. Biomed Res Int 2017:8201672 PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Schnorbach MT, Kruis W (2021) Cost of illness of inflammatory bowel disease in Germany. Z Gastroenterol 59(11):1173–1188 PubMed Schnorbach MT, Kruis W (2021) Cost of illness of inflammatory bowel disease in Germany. Z Gastroenterol 59(11):1173–1188 PubMed
7.
Zurück zum Zitat Stark R, Konig HH, Leidl R (2006) Costs of inflammatory bowel disease in Germany. PharmacoEconomics 24(8):797–814 PubMedCrossRef Stark R, Konig HH, Leidl R (2006) Costs of inflammatory bowel disease in Germany. PharmacoEconomics 24(8):797–814 PubMedCrossRef
8.
Zurück zum Zitat Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn’s disease. Lancet 389(10080):1741–1755 PubMedCrossRef Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn’s disease. Lancet 389(10080):1741–1755 PubMedCrossRef
9.
Zurück zum Zitat Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749–753 PubMedPubMedCentralCrossRef Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749–753 PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164 PubMedCrossRef Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164 PubMedCrossRef
11.
Zurück zum Zitat Authors C (2019) Updated S3-guideline ulcerative colitis. German society for digestive and metabolic diseases (DGVS). Z Gastroenterol 57(2):162–241 CrossRef Authors C (2019) Updated S3-guideline ulcerative colitis. German society for digestive and metabolic diseases (DGVS). Z Gastroenterol 57(2):162–241 CrossRef
13.
Zurück zum Zitat Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohns-Disease—a prospective multicenter study. Gut 30(7):983–989 PubMedPubMedCentralCrossRef Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohns-Disease—a prospective multicenter study. Gut 30(7):983–989 PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V et al (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60(4):505–512 PubMedCrossRef Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V et al (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60(4):505–512 PubMedCrossRef
15.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (1990) Predictability of the postoperative course of Crohns-Disease. Gastroenterol 99(4):956–963 CrossRef Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (1990) Predictability of the postoperative course of Crohns-Disease. Gastroenterol 99(4):956–963 CrossRef
16.
Zurück zum Zitat Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25 PubMedCrossRef Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25 PubMedCrossRef
18.
Zurück zum Zitat Burri E, Beglinger C (2014) The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroent 8(2):197–210 CrossRef Burri E, Beglinger C (2014) The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroent 8(2):197–210 CrossRef
19.
Zurück zum Zitat Hong SW, Yoon H, Shin CM, Park YS, Kim N, Lee DH et al (2020) Clinical significance of granulomas in Crohn’s disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 35(3):364–373 PubMedCrossRef Hong SW, Yoon H, Shin CM, Park YS, Kim N, Lee DH et al (2020) Clinical significance of granulomas in Crohn’s disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 35(3):364–373 PubMedCrossRef
20.
Zurück zum Zitat Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68(Suppl 3):s1–s106 PubMedCrossRef Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68(Suppl 3):s1–s106 PubMedCrossRef
21.
Zurück zum Zitat Sorensen LT, Malaki A, Wille-Jorgensen P, Kallehave F, Kjaergaard J, Hemmingsen U et al (2007) Risk factors for mortality and postoperative complications after gastrointestinal surgery. J Gastrointest Surg 11(7):903–910 PubMedCrossRef Sorensen LT, Malaki A, Wille-Jorgensen P, Kallehave F, Kjaergaard J, Hemmingsen U et al (2007) Risk factors for mortality and postoperative complications after gastrointestinal surgery. J Gastrointest Surg 11(7):903–910 PubMedCrossRef
22.
Zurück zum Zitat Rogler G, Singh A, Kavanaugh A, Rubin DT (2021) Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology 161(4):1118–1132 PubMedCrossRef Rogler G, Singh A, Kavanaugh A, Rubin DT (2021) Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology 161(4):1118–1132 PubMedCrossRef
23.
Zurück zum Zitat Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV et al (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110(9):1324–1338 PubMedCrossRef Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV et al (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110(9):1324–1338 PubMedCrossRef
24.
Zurück zum Zitat Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM et al (2021) STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 160(5):1570–1583 PubMedCrossRef Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM et al (2021) STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 160(5):1570–1583 PubMedCrossRef
25.
Zurück zum Zitat Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 14(1):4–22 PubMedCrossRef Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 14(1):4–22 PubMedCrossRef
26.
Zurück zum Zitat Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R et al (2017) Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network meta-analysis: republished. Inflamm Bowel Dis 23(5):E26–E37 PubMedCrossRef Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R et al (2017) Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network meta-analysis: republished. Inflamm Bowel Dis 23(5):E26–E37 PubMedCrossRef
27.
Zurück zum Zitat Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V et al (2019) Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 68(3):423–433 PubMedCrossRef Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V et al (2019) Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 68(3):423–433 PubMedCrossRef
28.
Zurück zum Zitat Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharm Ther 15(10):1515–1525 CrossRef Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharm Ther 15(10):1515–1525 CrossRef
29.
Zurück zum Zitat Gionchetti P, Dignass A, Danese S, Dias FJM, Rogler G, Lakatos PL et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11(2):135–149 PubMedCrossRef Gionchetti P, Dignass A, Danese S, Dias FJM, Rogler G, Lakatos PL et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11(2):135–149 PubMedCrossRef
30.
Zurück zum Zitat Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A (2019) Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. Bmj Open 9(3):e27428 PubMedPubMedCentralCrossRef Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A (2019) Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. Bmj Open 9(3):e27428 PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Swaminath A, Lebwohl B, Capiak KM, Present DH (2011) Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn’s disease: a US national practice survey comparing experts and non-experts. Digest Dis Sci 56(4):1160–1164 PubMedCrossRef Swaminath A, Lebwohl B, Capiak KM, Present DH (2011) Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn’s disease: a US national practice survey comparing experts and non-experts. Digest Dis Sci 56(4):1160–1164 PubMedCrossRef
32.
Zurück zum Zitat Nielsen OH, Ainsworth MA (2013) Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369(8):754–762 PubMedCrossRef Nielsen OH, Ainsworth MA (2013) Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369(8):754–762 PubMedCrossRef
33.
Zurück zum Zitat Fine S, Papamichael K, Cheifetz AS (2019) Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (n Y) 15(12):656–665 PubMed Fine S, Papamichael K, Cheifetz AS (2019) Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (n Y) 15(12):656–665 PubMed
34.
Zurück zum Zitat Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13(1):24–30 PubMedCrossRef Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13(1):24–30 PubMedCrossRef
35.
Zurück zum Zitat Gisbert JP, Panes J (2009) Loss of response and requirement of Infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104(3):760–767 PubMed Gisbert JP, Panes J (2009) Loss of response and requirement of Infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104(3):760–767 PubMed
36.
Zurück zum Zitat Gisbert JP, Chaparro M (2020) Predictors of primary response to biologic treatment [anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 14(5):694–709 PubMedCrossRef Gisbert JP, Chaparro M (2020) Predictors of primary response to biologic treatment [anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 14(5):694–709 PubMedCrossRef
37.
Zurück zum Zitat Apostolaki M, Armaka M, Victoratos P, Kollias G (2010) Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 11:1–26 PubMedCrossRef Apostolaki M, Armaka M, Victoratos P, Kollias G (2010) Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 11:1–26 PubMedCrossRef
38.
Zurück zum Zitat D’Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L et al (2022) Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results. Gastroenterology 162(7):1876–1890 PubMedCrossRef D’Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L et al (2022) Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results. Gastroenterology 162(7):1876–1890 PubMedCrossRef
39.
Zurück zum Zitat Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D et al (2007) Certolizumab pegol for the treatment of Crohn’s disease. New Engl J Med 357(3):228–238 PubMedCrossRef Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D et al (2007) Certolizumab pegol for the treatment of Crohn’s disease. New Engl J Med 357(3):228–238 PubMedCrossRef
40.
Zurück zum Zitat Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R et al (2014) Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3):618 PubMedCrossRef Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R et al (2014) Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3):618 PubMedCrossRef
41.
Zurück zum Zitat Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. New Engl J Med 369(8):711–721 PubMedCrossRef Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. New Engl J Med 369(8):711–721 PubMedCrossRef
42.
Zurück zum Zitat Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE et al (2020) Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharm Ther 52(8):1353–1365 CrossRef Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE et al (2020) Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharm Ther 52(8):1353–1365 CrossRef
43.
Zurück zum Zitat European Medicine Agency. Entyvio Summary of Product Characteristics.2014. European Medicine Agency. Entyvio Summary of Product Characteristics.2014.
44.
Zurück zum Zitat Ryan C, Thrash B, Warren RB, Menter A (2010) The use of ustekinumab in autoimmune disease. Expert Opin Biol Th 10(4):587–604 CrossRef Ryan C, Thrash B, Warren RB, Menter A (2010) The use of ustekinumab in autoimmune disease. Expert Opin Biol Th 10(4):587–604 CrossRef
45.
46.
Zurück zum Zitat Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. New Engl J Med 375(20):1946–1960 PubMedCrossRef Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. New Engl J Med 375(20):1946–1960 PubMedCrossRef
47.
Zurück zum Zitat Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. New Engl J Med 367(16):1519–1528 PubMedCrossRef Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. New Engl J Med 367(16):1519–1528 PubMedCrossRef
49.
Zurück zum Zitat Guillo L, D’Amico F, Danese S, Peyrin-Biroulet L (2021) Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. J Crohns Colitis 15(7):1236–1243 PubMedCrossRef Guillo L, D’Amico F, Danese S, Peyrin-Biroulet L (2021) Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. J Crohns Colitis 15(7):1236–1243 PubMedCrossRef
50.
Zurück zum Zitat Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C et al (2021) Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study. Gastroenterology 161(2):E30–E1 CrossRef Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C et al (2021) Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study. Gastroenterology 161(2):E30–E1 CrossRef
51.
Zurück zum Zitat Narula N, Wong ECL, Dulai PS, Sengupta NK, Marshall JK, Colombel JF et al (2022) Comparative efficacy and rapidity of action for Infliximab vs Ustekinumab in biologic naive Crohn’s disease. Clin Gastroenterol H 20(7):1579 CrossRef Narula N, Wong ECL, Dulai PS, Sengupta NK, Marshall JK, Colombel JF et al (2022) Comparative efficacy and rapidity of action for Infliximab vs Ustekinumab in biologic naive Crohn’s disease. Clin Gastroenterol H 20(7):1579 CrossRef
52.
Zurück zum Zitat Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B et al (2020) IM-UNITI: three-year efficacy, safety, and Immunogenicity of Ustekinumab treatment of Crohn’s disease. J Crohns Colitis 14(1):23–32 PubMedCrossRef Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B et al (2020) IM-UNITI: three-year efficacy, safety, and Immunogenicity of Ustekinumab treatment of Crohn’s disease. J Crohns Colitis 14(1):23–32 PubMedCrossRef
53.
Zurück zum Zitat Ma C, Jairath V, Khanna R, Feagan BG (2018) Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opin Inv Drug 27(8):649–660 CrossRef Ma C, Jairath V, Khanna R, Feagan BG (2018) Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opin Inv Drug 27(8):649–660 CrossRef
56.
Zurück zum Zitat D’Haens GR, Colombel JF, Bossuyt P, Danese S, Lim A, Lindsay J et al (2021) Risankizumab induction therapy in patients with moderate-to-severe Crohn’s disease with intolerance or inadequate response to conventional and/or biologic therapy: results from the phase 3 ADVANCE study. Gastroenterology 161(2):E28 CrossRef D’Haens GR, Colombel JF, Bossuyt P, Danese S, Lim A, Lindsay J et al (2021) Risankizumab induction therapy in patients with moderate-to-severe Crohn’s disease with intolerance or inadequate response to conventional and/or biologic therapy: results from the phase 3 ADVANCE study. Gastroenterology 161(2):E28 CrossRef
57.
Zurück zum Zitat Panaccione R, Schreiber S, Peyrin-Biroulet L, Loftus EV, Dubinsky M, Ferrante M et al (2021) Risankizumab as induction therapy in patients with moderately to severely active Crohn’s disease who failed 1 vs 〉 1 prior biologic treatment: results from the MOTIVATE study. Am J Gastroenterol 116:348 CrossRef Panaccione R, Schreiber S, Peyrin-Biroulet L, Loftus EV, Dubinsky M, Ferrante M et al (2021) Risankizumab as induction therapy in patients with moderately to severely active Crohn’s disease who failed 1 vs 〉 1 prior biologic treatment: results from the MOTIVATE study. Am J Gastroenterol 116:348 CrossRef
58.
Zurück zum Zitat Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S et al (2022) Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399(10340):2031–2046 PubMedCrossRef Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S et al (2022) Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399(10340):2031–2046 PubMedCrossRef
59.
Zurück zum Zitat Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S et al (2019) Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut 68(5):814–828 PubMedCrossRef Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S et al (2019) Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut 68(5):814–828 PubMedCrossRef
60.
Zurück zum Zitat Colombel JF, Sandborn WJ, Rutgeerts P (2010) Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease REPLY. New Engl J Med 363(11):1087–1088 Colombel JF, Sandborn WJ, Rutgeerts P (2010) Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease REPLY. New Engl J Med 363(11):1087–1088
61.
Zurück zum Zitat Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E et al (2013) Addition of an immunomodulator to Infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol H 11(4):444–447 CrossRef Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E et al (2013) Addition of an immunomodulator to Infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol H 11(4):444–447 CrossRef
62.
Zurück zum Zitat Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D’Haens GR (2017) Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharm Ther 45(8):1128–1134 CrossRef Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D’Haens GR (2017) Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharm Ther 45(8):1128–1134 CrossRef
63.
Zurück zum Zitat Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE et al (2020) Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut 69(7):1206–1212 PubMedCrossRef Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE et al (2020) Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut 69(7):1206–1212 PubMedCrossRef
64.
Zurück zum Zitat Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A et al (2015) Concentrations of 6‑Thioguanine nucleotide correlate with trough levels of Infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol H 13(6):1118 CrossRef Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A et al (2015) Concentrations of 6‑Thioguanine nucleotide correlate with trough levels of Infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol H 13(6):1118 CrossRef
65.
Zurück zum Zitat Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J et al (2023) Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol 8(4):307–320 PubMedCrossRef Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J et al (2023) Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol 8(4):307–320 PubMedCrossRef
66.
Zurück zum Zitat Agency EM (2013) CHMP assessment report Remsima [EMA/CHMP/589317/2013]. EMA, London Agency EM (2013) CHMP assessment report Remsima [EMA/CHMP/589317/2013]. EMA, London
67.
Zurück zum Zitat Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J et al (2017) ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohns Colitis 11(1):26–34 PubMedCrossRef Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J et al (2017) ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohns Colitis 11(1):26–34 PubMedCrossRef
68.
Zurück zum Zitat Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A et al (2019) Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 393(10182):1699–1707 PubMedCrossRef Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A et al (2019) Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 393(10182):1699–1707 PubMedCrossRef
69.
Zurück zum Zitat Wasserbauer M, Hlava S, Drabek J, Stovicek J, Minarikova P, Nedbalova L et al (2022) Adalimumab biosimilars in the therapy of Crohn’s disease and ulcerative colitis: Prospective multicentric clinical monitoring. PLoS ONE 17(8):e271299 PubMedPubMedCentralCrossRef Wasserbauer M, Hlava S, Drabek J, Stovicek J, Minarikova P, Nedbalova L et al (2022) Adalimumab biosimilars in the therapy of Crohn’s disease and ulcerative colitis: Prospective multicentric clinical monitoring. PLoS ONE 17(8):e271299 PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat D’Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C et al (2021) Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmun Rev 20(7):102849 PubMedCrossRef D’Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C et al (2021) Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmun Rev 20(7):102849 PubMedCrossRef
71.
Zurück zum Zitat Ma C (2022) To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol 20(8):1668–1670 PubMedCrossRef Ma C (2022) To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol 20(8):1668–1670 PubMedCrossRef
72.
Zurück zum Zitat Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D et al (2012) Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after Infliximab therapy is stopped. Gastroenterology 142(1):63–U201 PubMedCrossRef Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D et al (2012) Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after Infliximab therapy is stopped. Gastroenterology 142(1):63–U201 PubMedCrossRef
73.
Zurück zum Zitat Gisbert JP, Marin AC, Chaparro M (2016) The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 111(5):632–647 PubMedCrossRef Gisbert JP, Marin AC, Chaparro M (2016) The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 111(5):632–647 PubMedCrossRef
74.
Zurück zum Zitat Reenaers C, Mary JY, Nachury M, Bouhnik Y, Laharie D, Allez M et al (2018) Outcomes 7 years after Infliximab withdrawal for patients with Crohn’s disease in sustained. Remission Clin Gastroenterol H 16(2):234 CrossRef Reenaers C, Mary JY, Nachury M, Bouhnik Y, Laharie D, Allez M et al (2018) Outcomes 7 years after Infliximab withdrawal for patients with Crohn’s disease in sustained. Remission Clin Gastroenterol H 16(2):234 CrossRef
75.
Zurück zum Zitat Chaparro MMGD, Riestra S, Lucendo AJ et al (2023) Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT). J Crohn’s Colitis 17:i50–i4 CrossRef Chaparro MMGD, Riestra S, Lucendo AJ et al (2023) Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT). J Crohn’s Colitis 17:i50–i4 CrossRef
76.
Zurück zum Zitat Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A et al (2018) European Crohn’s and colitis organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J Crohns Colitis 12(1):17–31 PubMedCrossRef Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A et al (2018) European Crohn’s and colitis organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J Crohns Colitis 12(1):17–31 PubMedCrossRef
77.
Zurück zum Zitat Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V et al (2016) Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol H 14(1):58–64 CrossRef Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V et al (2016) Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol H 14(1):58–64 CrossRef
78.
Zurück zum Zitat Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F et al (2017) Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. J Am Med Assoc 318(17):1679–1686 CrossRef Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F et al (2017) Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. J Am Med Assoc 318(17):1679–1686 CrossRef
79.
Zurück zum Zitat Dahmus J, Rosario M, Clarke K (2020) Risk of lymphoma associated with anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol 13:339–350 PubMedCentralCrossRef Dahmus J, Rosario M, Clarke K (2020) Risk of lymphoma associated with anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol 13:339–350 PubMedCentralCrossRef
80.
Zurück zum Zitat Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L et al (2019) The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 13(5):541–554 PubMedCrossRef Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L et al (2019) The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 13(5):541–554 PubMedCrossRef
81.
Zurück zum Zitat Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X et al (2017) Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389(10066):266–275 PubMedCrossRef Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X et al (2017) Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389(10066):266–275 PubMedCrossRef
82.
Zurück zum Zitat Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D’Haens G et al (2020) Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology 158(8):2123 PubMedCrossRef Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D’Haens G et al (2020) Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology 158(8):2123 PubMedCrossRef
83.
Zurück zum Zitat Hohenberger M, Cardwell LA, Oussedik E, Feldman SR (2018) Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 29(1):13–18 PubMedCrossRef Hohenberger M, Cardwell LA, Oussedik E, Feldman SR (2018) Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 29(1):13–18 PubMedCrossRef
84.
Zurück zum Zitat Schwartz DA, Loftus EV, Tremaine WJ, Pannaccione R, Sandborn WJ (2000) The natural history of fistulizing Crohn’s disease: A population-based study. Gastroenterology 118(4):A337 CrossRef Schwartz DA, Loftus EV, Tremaine WJ, Pannaccione R, Sandborn WJ (2000) The natural history of fistulizing Crohn’s disease: A population-based study. Gastroenterology 118(4):A337 CrossRef
85.
Zurück zum Zitat Bergstrand O, Ewerth S, Hellers G, Holmstrom B, Ullman J, Wallberg P (1980) Outcome following treatment of anal fistulae in Crohn’s disease. Acta Chir Scand Suppl 500:43–44 PubMed Bergstrand O, Ewerth S, Hellers G, Holmstrom B, Ullman J, Wallberg P (1980) Outcome following treatment of anal fistulae in Crohn’s disease. Acta Chir Scand Suppl 500:43–44 PubMed
86.
Zurück zum Zitat Hellers G, Bergstrand O, Ewerth S, Holmstrom B (1980) Occurrence and outcome after primary-treatment of anal fistulas in Crohns-disease. Gut 21(6):525–527 PubMedPubMedCentralCrossRef Hellers G, Bergstrand O, Ewerth S, Holmstrom B (1980) Occurrence and outcome after primary-treatment of anal fistulas in Crohns-disease. Gut 21(6):525–527 PubMedPubMedCentralCrossRef
87.
Zurück zum Zitat Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA (2003) The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther 17(9):1145–1151 PubMedCrossRef Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA (2003) The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther 17(9):1145–1151 PubMedCrossRef
88.
Zurück zum Zitat Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice C (2003) AGA technical review on perianal Crohn’s disease. Gastroenterology 125(5):1508–1530 PubMedCrossRef Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice C (2003) AGA technical review on perianal Crohn’s disease. Gastroenterology 125(5):1508–1530 PubMedCrossRef
89.
Zurück zum Zitat Parks AG, Gordon PH, Hardcastle JD (1976) A classification of fistula-in-ano. Br J Surg 63(1):1–12 PubMedCrossRef Parks AG, Gordon PH, Hardcastle JD (1976) A classification of fistula-in-ano. Br J Surg 63(1):1–12 PubMedCrossRef
90.
Zurück zum Zitat Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ (2014) Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis 20(11):2022–2028 PubMedCrossRef Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ (2014) Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis 20(11):2022–2028 PubMedCrossRef
91.
Zurück zum Zitat Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF et al (2013) Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 11(8):975–81 e1–4 PubMedCrossRef Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF et al (2013) Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 11(8):975–81 e1–4 PubMedCrossRef
92.
Zurück zum Zitat Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis 14(2):155–168 PubMedCrossRef Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis 14(2):155–168 PubMedCrossRef
93.
Zurück zum Zitat Meima-van Praag EM, van Rijn KL, Wasmann K, Snijder HJ, Stoker J, D’Haens GR et al (2022) Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol 7(7):617–626 PubMedCrossRef Meima-van Praag EM, van Rijn KL, Wasmann K, Snijder HJ, Stoker J, D’Haens GR et al (2022) Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol 7(7):617–626 PubMedCrossRef
94.
Zurück zum Zitat Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH et al (2015) Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 42(7):783–792 PubMedPubMedCentralCrossRef Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH et al (2015) Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 42(7):783–792 PubMedPubMedCentralCrossRef
95.
Zurück zum Zitat Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY et al (2015) Effects of concomitant Immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol H 13(13):2233 CrossRef Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY et al (2015) Effects of concomitant Immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol H 13(13):2233 CrossRef
96.
Zurück zum Zitat Peyrin-Biroulet LRP, Gasink C, Hoops T et al (2022) Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials. J Crohn’s Colitis 16:460 CrossRef Peyrin-Biroulet LRP, Gasink C, Hoops T et al (2022) Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials. J Crohn’s Colitis 16:460 CrossRef
97.
Zurück zum Zitat Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J et al (2018) Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis 12(5):621–626 PubMedPubMedCentralCrossRef Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J et al (2018) Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis 12(5):621–626 PubMedPubMedCentralCrossRef
98.
Zurück zum Zitat Gingold DS, Murrell ZA, Fleshner PR (2014) A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg 260(6):1057–1061 PubMedCrossRef Gingold DS, Murrell ZA, Fleshner PR (2014) A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg 260(6):1057–1061 PubMedCrossRef
99.
Zurück zum Zitat Soltani A, Kaiser AM (2010) Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum 53(4):486–495 PubMedCrossRef Soltani A, Kaiser AM (2010) Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum 53(4):486–495 PubMedCrossRef
100.
Zurück zum Zitat Prosst RL, Herold A, Joos AK, Bussen D, Wehrmann M, Gottwald T et al (2012) The anal fistula claw: the OTSC clip for anal fistula closure. Colorectal Dis 14(9):1112–1117 PubMedCrossRef Prosst RL, Herold A, Joos AK, Bussen D, Wehrmann M, Gottwald T et al (2012) The anal fistula claw: the OTSC clip for anal fistula closure. Colorectal Dis 14(9):1112–1117 PubMedCrossRef
101.
Zurück zum Zitat Senejoux A, Siproudhis L, Abramowitz L, Munoz-Bongrand N, Desseaux K, Bouguen G et al (2016) Fistula plug in fistulising ano-perineal Crohn’s disease: a randomised controlled trial. J Crohns Colitis 10(2):141–148 PubMedCrossRef Senejoux A, Siproudhis L, Abramowitz L, Munoz-Bongrand N, Desseaux K, Bouguen G et al (2016) Fistula plug in fistulising ano-perineal Crohn’s disease: a randomised controlled trial. J Crohns Colitis 10(2):141–148 PubMedCrossRef
102.
Zurück zum Zitat Alam A, Lin F, Fathallah N, Pommaret E, Aubert M, Lemarchand N et al (2020) FiLaC((R)) and Crohn’s disease perianal fistulas: a pilot study of 20 consecutive patients. Tech Coloproctol 24(1):75–78 PubMedCrossRef Alam A, Lin F, Fathallah N, Pommaret E, Aubert M, Lemarchand N et al (2020) FiLaC((R)) and Crohn’s disease perianal fistulas: a pilot study of 20 consecutive patients. Tech Coloproctol 24(1):75–78 PubMedCrossRef
103.
Zurück zum Zitat Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10):3499–3506 PubMedCrossRef Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10):3499–3506 PubMedCrossRef
104.
Zurück zum Zitat Cao Y, Su Q, Zhang B, Shen F, Li S (2021) Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther 12(1):32 PubMedPubMedCentralCrossRef Cao Y, Su Q, Zhang B, Shen F, Li S (2021) Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther 12(1):32 PubMedPubMedCentralCrossRef
106.
Zurück zum Zitat Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A et al (2017) Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2(11):785–792 PubMedCrossRef Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A et al (2017) Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2(11):785–792 PubMedCrossRef
107.
Zurück zum Zitat Agrawal M, Ebert A, Poulsen G, Ungaro R (2023) OP11 Ileocecal resection for recently diagnosed ileocecal Crohn’s disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based study Agrawal M, Ebert A, Poulsen G, Ungaro R (2023) OP11 Ileocecal resection for recently diagnosed ileocecal Crohn’s disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based study
108.
Zurück zum Zitat Cohen BL, Fleshner P, Kane SV, Herfarth HH, Palekar N, Farraye FA et al (2022) Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology 163(1):204–221 PubMedCrossRef Cohen BL, Fleshner P, Kane SV, Herfarth HH, Palekar N, Farraye FA et al (2022) Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology 163(1):204–221 PubMedCrossRef
109.
Zurück zum Zitat Manser C, Maillard MH, Rogler G, Schreiner P, Rieder F, Bühler S (2020) Vaccination in patients with inflammatory bowel diseases. Digestion 101:58–68 PubMedCrossRef Manser C, Maillard MH, Rogler G, Schreiner P, Rieder F, Bühler S (2020) Vaccination in patients with inflammatory bowel diseases. Digestion 101:58–68 PubMedCrossRef
111.
Zurück zum Zitat Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C et al (2021) ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohn’s Colitis 15(6):879–913 CrossRef Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C et al (2021) ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohn’s Colitis 15(6):879–913 CrossRef
112.
Zurück zum Zitat Caldera F, Hayney MS, Farraye FA (2020) Vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 115:1356–1361 CrossRef Caldera F, Hayney MS, Farraye FA (2020) Vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 115:1356–1361 CrossRef
Metadaten
Titel
Morbus Crohn Update
verfasst von
Dr. med. Andrea S. Kreienbuehl
PD Dr. med. Luc Biedermann
Publikationsdatum
07.06.2023
Verlag
Springer Vienna
Schlagwort
Morbus Crohn
Erschienen in
Schweizer Gastroenterologie / Ausgabe 2/2023
Print ISSN: 2662-7140
Elektronische ISSN: 2662-7159
DOI
https://doi.org/10.1007/s43472-023-00097-3

Weitere Artikel der Ausgabe 2/2023

Schweizer Gastroenterologie 2/2023 Zur Ausgabe

Editoriale

Editoriale

Aktuell

Aktuell

Editorial

Editorial